Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lobaplatin + etoposide versus cisplatin + etoposide for extensive-stage small cell lung cancer
ChiCTR1800017254Phase 4Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Xinjiang Medical University
- Start
- Sep 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of lobaplatin, cisplatin and etoposide in small cell lung cancer (SCLC) (2 arms), sponsored by Affiliated Cancer Hospital of Xinjiang Medical University. Primary endpoints: Leukocyte and Carcinoembryonic antigen. Planned start Sep 2018; status: not yet recruiting.
02
Drugs
lobaplatincisplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR1800017254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017254.